Thermo Fisher Scientific (NYSE:TMO) Partners With Cybin For Phase 3 Depression Treatment
Thermo Fisher Scientific recently partnered with Cybin Inc. to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, a promising treatment for Major Depressive Disorder. Despite this partnership news, the company’s stock price was flat last week, in contrast to a positive broader market trend marked by a 5.1% rise. Factors such as the overall market sentiment driven by strong economic data and earnings reports likely influenced stock movements more significantly, while Thermo Fisher’s recent developments added a counterbalancing weight to the modest movement.
Be aware that Thermo Fisher Scientific is showing 2 possible red flags in our investment analysis.
